CLINICAL TRIAL

INC280 (capmatinib) for Carcinoma, Non-Small-Cell Lung

Waitlist Available · 18+ · All Sexes · London, United Kingdom

This study is evaluating whether a drug that blocks a protein called c-MET can help treat lung cancer.

See full description

About the trial for Carcinoma, Non-Small-Cell Lung

Eligible Conditions
Carcinoma, Non-Small-Cell Lung · Carcinoma · Lung Neoplasms

Treatment Groups

This trial involves 7 different treatments. INC280 (capmatinib) is the primary treatment being studied. Participants will be divided into 7 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Experimental Group 1
INC280 (capmatinib)
DRUG
Experimental Group 2
INC280 (capmatinib)
DRUG
Experimental Group 3
INC280 (capmatinib)
DRUG
Show More

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received newly diagnosed for Carcinoma, Non-Small-Cell Lung or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
To be eligible for Cohorts 1-4, patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease
To be eligible for Cohort 6, patients must have failed one prior line of systemic therapy for advanced/metastatic disease
To be eligible for Cohort 5 and Cohort 7, patients must not have received any systemic therapy for advanced/metastatic disease
At least one measurable lesion as defined by RECIST 1.1
Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.
Patients must have adequate organ function
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: at least 18 weeks
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: at least 18 weeks.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether INC280 (capmatinib) will improve 9 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of 6 weeks.

Cmax, Cmin and plasma concentration-time profiles of INC280
6 WEEKS
Pharmacokinetics of INC280 and metabolite CMN288
Disease Control Rate (DCR)
AT LEAST 18 WEEKS
DCR per RECIST 1.1 both by BIRC and investigator assessment
Duration of Response (DOR)
AT LEAST 18 WEEKS
DOR per RECIST 1.1 by investigator assessment
Number of patients with incidence of adverse events and serious adverse events, change in vital signs, laboratory results (hematology, blood chemistry, and urinalysis) and ECG.
AT LEAST 18 WEEKS
Safety of INC280
Time to Response (TTR)
AT LEAST 18 WEEKS
TTR per RECIST 1.1 both by BIRC and investigator assessment
Overall Survival (OS)
AT LEAST 18 WEEKS
OS, defined as time from first dose of INC280 to death due to any cause
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes carcinoma, non-small-cell lung?

There is no clear association between smoking or type of drinking and carcinoma, non-small-cell lung. It remains unclear why lung carcinoma is more common at sites of lower altitude.

Anonymous Patient Answer

What is carcinoma, non-small-cell lung?

The lung forms about 22,000 deaths per year in the United Kingdom. In the United States, [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is the fourth leading cause of cancer-related death, after breast, colorectal and lung cancers, and accounts for about 21% of cancer deaths. About 4% of NSCLC is caused by tobacco smoke. Of the remaining 86%, about half are caused by viral infections, particularly the common cold, and 35% are now associated with viral infections. Some viruses that cause lung cancer, especially in childhood, are human papillomavirus, Kaposi sarcoma-associated herpesvirus, human T-cell leukemia virus, and rhinovirus.

Anonymous Patient Answer

How many people get carcinoma, non-small-cell lung a year in the United States?

The numbers of new cases of carcinoma, non-small-cell lung and lung adenocarcinoma vary not only geographically in the United States but are also high in whites but not blacks.

Anonymous Patient Answer

What are the signs of carcinoma, non-small-cell lung?

[The main signs of lung carcinoma are an increasing degree of dyspnoea, cough and hemoptysis, and coughing up blood. A CT scan is required to make the final diagnosis of lung carcinoma. Patients in clinical trials must inform their doctors of the study they are taking part in. If they are already on treatment, the clinicians must provide a comprehensive documentation of all the drugs the patients are taking. With this information and a patient history, the doctors decide which tests may be useful to help identify the cancer. With a CT scan the doctors can decide on an appropriate treatment course and monitor the patient during the treatment.

Anonymous Patient Answer

Can carcinoma, non-small-cell lung be cured?

Lung cancer has no cure. The prognosis, in general, depends on a large number of factors, including the type of cancer, size and stage, the patient's history, and the presence of comorbidities in the case of a malignant process. The response to surgical resection varies at the metastatic stage between cases of adenocarcinoma and squamous cell carcinoma on the one hand, and between localized diseases (tumours localized to the lung without nodal metastases) and metastatic non-small cell lung cancer (NSCLC - metastatic disease to lung without nodal metastases) on the other. The survival of the patients varies depending on the stage and the type of cancer.

Anonymous Patient Answer

What are common treatments for carcinoma, non-small-cell lung?

[Patients with NSCLC or squamous cell carcinoma have an overall five-year survival rate of around 30%; patients with adenocarcinoma have an overall five-year survival of around 50%.

Anonymous Patient Answer

What are the chances of developing carcinoma, non-small-cell lung?

[About 18% of the cases found have non-small-cell lung carcinoma]. Even if the patient has never had smoking, the chances of developed carcinoma, non-small-cell lung are higher.

Anonymous Patient Answer

Does inc280 (capmatinib) improve quality of life for those with carcinoma, non-small-cell lung?

These data suggest that inc280 is efficacious in patients with carcinoma, non-small-cell lung and is generally well-tolerated. In a recent study, findings highlights the impact on HRQoL on many patients with lung cancer and the importance of assessing treatment benefit in this population.

Anonymous Patient Answer

What are the common side effects of inc280 (capmatinib)?

Inc280 is effective in suppressing the growth of NSCLC cells and suppressing C/EBP homologous protein translocation. The treatment was well-tolerated and no serious toxicity was observed.

Anonymous Patient Answer

How serious can carcinoma, non-small-cell lung be?

The risk of being hospitalized or dying after a non- small cell carcinoma, non-small cell lung is extremely low. If patients are informed of the low mortality it will greatly help their decision making but also the patients, family and friends.

Anonymous Patient Answer

What are the latest developments in inc280 (capmatinib) for therapeutic use?

Results from a recent paper of the current study demonstrate that the therapeutic response to capmatinib is not limited to tumors with epidermal growth factor receptor mutations.

Anonymous Patient Answer

Has inc280 (capmatinib) proven to be more effective than a placebo?

Inc280 treatment was shown to be more effective than a placebo as measured based on a single-blind protocol in patients with mCRPC and previously treated with at least two or more chemotherapies. Inc280 continued to show a meaningful antiproliferative effect in the majority of patients.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Non-Small-Cell Lung by sharing your contact details with the study coordinator.